中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer

文献类型：期刊论文

作者Tong, Ying-Hui2; Hu, Xiao-Ping1; Xiang, Xue-Ping3; Fang, Luo2
刊名TRANSLATIONAL CANCER RESEARCH
出版日期2021-03-01
卷号10
关键词Monocarboxylate transporter 1 (MCT1) monocarboxylate transporter 4 (MCT4) prognosis non-small cell lung cancer (NSCLC)
ISSN号2218-676X
DOI10.21037/tcr-20-3117
通讯作者Xiang, Xue-Ping(xiangxueping@zju.edu.cn) ; Fang, Luo(Fangluo@zjcc.org.cn)
英文摘要Background: The monocarboxylate transporter (MCT) family especially MCT1 and MCT4 have been recognized to play an important role in lactate transport, a key glycolytic product. The expression of MCT1 and MCT4 expression was previously found to be related to poor outcome in various cancer types. In this study, we investigated the expression status of MCT1 and MCT4 and their relationship with prognosis in non-small cell lung cancer (NSCLC). Methods: Expression of MCT4 and MCT1 in NSCLC tumor and adjacent lung tissues were detected by immunohistochemistry. Kaplan-Meier plots were used to evaluate two proteins' prognostic role, and the logrank test obtained the P value. For multivariate analysis, the Cox proportional-hazards regression method was performed. Results: High MCT4 and MCT1 expression was observed in cancer cells, with a rate of 45% for MCT4 versus 15% for MCT1 among all NSCLC patients. High expression of MCT4, and not MCT1, was associated with worse overall survival (OS) [hazard ratio (HR) =1.96 (1.06-3.75), P=0.032] and progressionfree survival (PFS) [HR =1.72 (1.05-2.93), P=0.032] in NSCLC patients. In our multivariate analysis, advanced cancer stage and high MCT4 level were identified as independent predictive indicators for both PFS [HR(MCT4) =1.888 (1.114-3.199), P=0.018 and OS [HR (MCT4) =2.421 (1.271-4.610), P=0.007]. Subgroup and interaction analyses were also performed in different clinical characteristic groups and no significant differences were observed. Conclusions: High MCT4 expression is a predictive marker for worse outcome in NSCLC patients.
资助项目National Natural Science Foundation of China[81803549] ; Natural Science Foundation of Zhejiang Province[LQ18H310002] ; Projects of Medical and Health Technology Program in Zhejiang Province[2018253186] ; Projects of Medical and Health Technology Program in Zhejiang Province[2015KYB061]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000635021300014
出版者AME PUBL CO
资助机构National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province ; Projects of Medical and Health Technology Program in Zhejiang Province
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/121594]  
专题中国科学院合肥物质科学研究院
通讯作者Xiang, Xue-Ping; Fang, Luo
作者单位1.Zhejiang Prov Peoples Hosp, Dept Pharm, Hangzhou, Peoples R China
2.Univ Chinese Acad Sci, Dept Pharm, Canc Hosp,Chinese Acad Sci, Zhejiang Canc Hosp,Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China
3.Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pathol, Hangzhou 310009, Peoples R China
推荐引用方式
GB/T 7714		 Tong, Ying-Hui,Hu, Xiao-Ping,Xiang, Xue-Ping,et al. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer[J]. TRANSLATIONAL CANCER RESEARCH,2021,10.
APA Tong, Ying-Hui,Hu, Xiao-Ping,Xiang, Xue-Ping,&Fang, Luo.(2021).High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer.TRANSLATIONAL CANCER RESEARCH,10.
MLA Tong, Ying-Hui,et al."High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer".TRANSLATIONAL CANCER RESEARCH 10(2021).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。